PATENT CLAIM ANALYSIS

Application Number: 16049390
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "464000"]

Abstract:
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Claim (Index 7):
A solid oral controlled release dosage form, comprising:\n (a) about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt thereof as the sole active ingredient; and (b) a controlled release matrix, comprising:\n (i) about 10% to about 75% (by total weight of the controlled release matrix) of a gelling agent which forms a gel upon exposure to gastrointestinal fluid; \n (ii) about 2% to about 15% (by total weight of the controlled release matrix) of a cationic crosslinking agent; and \n (iii) about 30% to about 75% (by total weight of the controlled release matrix) of a diluent; \n wherein the dosage form has a dissolution rate in vitro, when measured by USP Paddle Method at 50 rpm in 500 ml media having a pH between 1.2 and 6.8 at 37\u00b0 C., of about 15% to about 50% by weight oxymorphone released after 1 hour, about 45% to about 80% by weight oxymorphone released after 4 hours, and at least about 80% by weight oxymorphone released after 10 hours; and wherein upon oral administration of the dosage form to a subject in need of an analgesic effect:\n (i) the dosage form provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone; \n (ii) the blood plasma levels of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration; \n (iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of area under the curve (AUC (0 to inf) ) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5; and \n (iv) the duration of the analgesic effect is through at least about 12 hours after administration.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.18919
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11427438', '10190192', '11680432', '12716973', '14336753']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7761489617580788
- 35 USC 102 Novelty (BERT): 0.5871861296897529
- Combined Prediction Score: 0.7572526785512462
- Mean Citation Score: 463.99081000000007
- Max Citation Score: 525.475
- Similarity Product: 411.4065172225236

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test